Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
about
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysisCurrent status of theranostics in prostate cancer.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.
P2860
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preliminary experience with do ...... tion-resistant prostate cancer
@en
Preliminary experience with do ...... ion-resistant prostate cancer.
@nl
type
label
Preliminary experience with do ...... tion-resistant prostate cancer
@en
Preliminary experience with do ...... ion-resistant prostate cancer.
@nl
prefLabel
Preliminary experience with do ...... tion-resistant prostate cancer
@en
Preliminary experience with do ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Preliminary experience with do ...... tion-resistant prostate cancer
@en
P2093
Andreas Delker
Axel Rominger
Christian Gratzke
Franz J Gildehaus
Guido Böning
Harun Ilhan
Peter Bartenstein
Sebastian Lehner
Svenja Reinhardt
Wolfgang P Fendler
P2860
P304
P356
10.18632/ONCOTARGET.12240
P407
P577
2016-09-24T00:00:00Z